Chemomab Therapeutics (CCMB) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Company overview and lead asset

• Focuses on developing novel treatments for inflammatory and fibrotic diseases, with nebokitug as the lead monoclonal antibody targeting CCL24.

• Nebokitug has shown strong anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies across liver, skin, and lung.

• Target indications include primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), both rare diseases with high unmet need.

• Nebokitug holds Orphan Drug Designation from both EMA and FDA for PSC.

Clinical trial results and development plans

• Phase II study in PSC demonstrated safety, tolerability, and significant improvements in inflammatory and fibrotic biomarkers, especially in moderate to advanced disease.

• The 20 mg/kg dose is selected for phase III, focusing on patients with moderate to advanced PSC.

• After 48 weeks, patients showed continued biomarker improvement and an 80% reduction in clinical events compared to historical controls.

• Phase III will use clinical events as the primary endpoint, with potential for interim analysis and early BLA filing.

• Approximately 50% of PSC patients have moderate to advanced disease, the main target for phase III, but broader applicability is anticipated.

Market opportunity and competitive landscape

• PSC market estimated at over $1 billion in revenues, with potential to expand as new therapies become available.

• Nebokitug is positioned as the only late-stage disease-modifying therapy in PSC, targeting both inflammation and fibrosis.

• Systemic sclerosis represents a $1.5 billion market with no current disease-modifying drugs.

• Nebokitug's dual mechanism offers potential across multiple fibrotic and inflammatory indications.